Drug Profile
Research programme: cancer and CNS disorder therapeutics - VECT-HORUS
Alternative Names: VH-N439; VH-PaxLatest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator VECT-HORUS
- Class Anti-ischaemics; Antineoplastics; Drug conjugates; Neuroprotectants; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders
- Research Solid tumours
- No development reported Cerebral ischaemia; Lysosomal storage diseases; Pancreatic cancer
- Discontinued Adrenal cancer; Brain cancer; Hypoxia
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Pancreatic-cancer in France (Parenteral)
- 28 Jul 2021 No recent reports of development identified for preclinical development in Cerebral-ischaemia in France (Parenteral)
- 28 Jul 2021 No recent reports of development identified for research development in Lysosomal storage diseases in France (Parenteral)